Natera, Inc. is a global leader in cell-free DNA (cfDNA) testing and diagnostics. The company develops cutting-edge genetic testing solutions to advance patient care in oncology, women's health, and organ health. Natera’s portfolio includes clinically validated tests such as Panorama®, a non-invasive prenatal test for chromosomal abnormalities; Horizon™, a carrier screening tool for inherited conditions; Signatera™, a personalized assay for detecting molecular residual disease in cancer; and Prospera™, which monitors organ transplant rejection through donor-derived cfDNA. Supported by over 250 peer-reviewed studies, Natera’s tests integrate advanced molecular biology, AI, and bioinformatics to deliver exceptional accuracy. Operating CAP-accredited and CLIA-certified labs, Natera is committed to making personalized genetic testing a standard of care, empowering earlier and more targeted medical interventions for improved outcomes.